Importantly, both treatments repressed the direct positive WNT-TCF targetsAXIN2,LGR5, andASCL2 in DLD1 and Ls174T colon cancer cells, although they had variable effects oncMYC (Fig2D). This evidence concerns the gene LGR5 and colonic neoplasm.